JPMorgan analyst Robbie Marcus initiated coverage of Heartflow (HTFL) with an Overweight rating and $36 price target The firm believes Heartflow is one of the “clearest and most pioneering downstream beneficiaries” of the artificial intelligence revolution in the healthcare sector. The company offers regulated healthcare and technology through its AI-enabled, diagnostic software for coronary artery disease, the analyst tells investors in a research note. JPMorgan says the company benefits from a capital-light business model with an “excellent” gross margin profile.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HTFL:
- HeartFlow, Inc.: Innovative Technology and Strong Financial Performance Drive Buy Rating
- HeartFlow, Inc.: Positioned for Growth in AI-Powered Coronary Diagnostics with Strong Market Potential
- Innovative AI-Driven Diagnostics Propel HeartFlow, Inc. to Buy Rating
- HeartFlow, Inc. Terminates Credit Agreement with Hayfin
- HeartFlow, Inc. Completes Successful IPO Raising $364 Million